Clinical Trial Update: Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Pregnyl as adjunct therapy for high-risk or refractory acute graft-versus-host disease has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• PREGNYL (Chorionic gonadotropin alfa)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Graft vs Host Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-12-14